Royalty Pharma plc Files Form 8-K

Ticker: RPRX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1802768

Royalty Pharma PLC 8-K Filing Summary
FieldDetail
CompanyRoyalty Pharma PLC (RPRX)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages5
Reading Time7 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, administrative

Related Tickers: RPRX

TL;DR

RPRX filed a 8-K confirming HQ and Nasdaq listing.

AI Summary

On January 13, 2025, Royalty Pharma plc (RPRX) filed a Form 8-K to report its current status. The filing confirms the company's principal executive offices are located at 110 East 59th Street, New York, New York, 10022. Royalty Pharma plc is incorporated in England and Wales and its Class A Ordinary Shares trade on The Nasdaq Stock Market LLC under the ticker RPRX.

Why It Matters

This filing serves as a standard notification of corporate information and confirms the company's operational base and stock exchange listing.

Risk Assessment

Risk Level: low — This is a routine administrative filing with no new material financial or operational information disclosed.

Key Players & Entities

FAQ

What is the primary purpose of this Form 8-K filing for Royalty Pharma plc?

The primary purpose is to report current information as required by the SEC, specifically confirming the company's principal executive offices and its incorporation details.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on January 13, 2025.

Where are Royalty Pharma plc's principal executive offices located?

Royalty Pharma plc's principal executive offices are located at 110 East 59th Street, New York, New York, 10022.

On which stock exchange are Royalty Pharma plc's Class A Ordinary Shares traded?

Royalty Pharma plc's Class A Ordinary Shares are traded on The Nasdaq Stock Market LLC.

What is the trading symbol for Royalty Pharma plc's Class A Ordinary Shares?

The trading symbol for Royalty Pharma plc's Class A Ordinary Shares is RPRX.

Filing Stats: 1,628 words · 7 min read · ~5 pages · Grade level 13.2 · Accepted 2025-01-13 08:40:45

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma's strategies, financing plans, growth opportunities, market growth, and plans for capital deployment, plus the benefits of the Transaction (as defined in the Current Report on Form 8-K filed with the SEC on January 10, 2025), including cash savings, enhanced alignment with shareholders, increased investment returns, expectations regarding management continuity, transparency and governance, and the benefits of simplification to its structure. In some cases, you can identify such forward-looking statements by terminology such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential" or "continue," the n

SIGNATURES

SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: January 13, 2025 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing